Cargando…

Activation of the Her2/neu receptor leads to antiestrogen resistance, but acquired resistance is not caused by altered ErbB expression and activation

Detalles Bibliográficos
Autores principales:	Larsen, SS, Lykkesfeldt, AE
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2000
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3300854/ http://dx.doi.org/10.1186/bcr156

Ejemplares similares

ErbB2/HER2/Neu resembles an autoinhibited invertebrate EGF receptor
por: Alvarado, Diego, et al.
Publicado: (2009)

Expression of oncogenes in thyroid tumours: coexpression of c-erbB2/neu and c-erbB.
por: Aasland, R., et al.
Publicado: (1988)

Structural basis for the oncogenic signalling complex formed by Grb2 and Gab2 in Her2 (ErbB2/Neu)-driven breast cancers and CML cells
por: Tsirka, T, et al.
Publicado: (2009)

Evaluation of C-ErbB-2 Overexpression and Her-2/neu Gene Copy Number Heterogeneity in Barrett’s Adenocarcinoma
por: Walch, Axel, et al.
Publicado: (2000)

Small Molecule Tyrosine Kinase Inhibitors of ErbB2/HER2/Neu in the Treatment of Aggressive Breast Cancer
por: Schroeder, Richard L., et al.
Publicado: (2014)

LMO4 is an essential mediator of ErbB2/HER2/Neu-induced breast cancer cell cycle progression
por: Montañez-Wiscovich, ME, et al.
Publicado: (2009)

Endocrine resistance in breast cancer: new roles for ErbB3 and ErbB4
por: Sutherland, Robert L
Publicado: (2011)

Pathway pathology: the wnt and erbB mammary tumors
por: Rosner, A, et al.
Publicado: (2001)

Combating acquired resistance to trastuzumab by an anti-ErbB2 fully human antibody
por: Wang, Chao, et al.
Publicado: (2017)

ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC
por: Alvarado, Diego, et al.
Publicado: (2017)

The Mysterious Ways of ErbB2/HER2 Trafficking
por: Bertelsen, Vibeke, et al.
Publicado: (2014)

Continuous requirement of ErbB2 kinase activity for loss of cell polarity and lumen formation in a novel ErbB2/Neu-driven murine cell line model of metastatic breast cancer
por: Ortega-Cava, Cesar F., et al.
Publicado: (2011)

Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer
por: Larsen, Sarah L, et al.
Publicado: (2015)

Mammary Cells with Active Wnt Signaling Resist ErbB2-Induced Tumorigenesis
por: Bu, Wen, et al.
Publicado: (2013)

Estrogen receptor transcription and transactivation: ErbB family of receptors in breast cancer
por: Hynes, NE, et al.
Publicado: (2001)

Altered signaling in anti-estrogen-resistant human breast cancer cells
por: Lykkesfeldt, AE, et al.
Publicado: (2005)

Prognostic value of ErbB2/HER2 in human meningiomas
por: Arnli, Magnus B., et al.
Publicado: (2018)

Serological Her2/neu-determination in patients receiving Herceptin(®)
por: Thomas, A, et al.
Publicado: (2001)

The pitfall of the transient, inconsistent anticancer capacity of antiestrogens and the mechanism of apparent antiestrogen resistance
por: Suba, Zsuzsanna
Publicado: (2015)

Src Drives Growth of Antiestrogen Resistant Breast Cancer Cell Lines and Is a Marker for Reduced Benefit of Tamoxifen Treatment
por: Larsen, Sarah L., et al.
Publicado: (2015)

The immunoglobulin‐like domain of neuregulins potentiates ErbB3/HER3 activation and cellular proliferation
por: Centa, Ariana, et al.
Publicado: (2018)

Activated Akt1 accelerates MMTV-c-ErbB2 mammary tumourigenesis in mice without activation of ErbB3
por: Young, Christian D, et al.
Publicado: (2008)

Modulation of ErbB2 Blockade in ErbB2-Positive Cancers: The Role of ErbB2 Mutations and PHLDA1
por: Li, Guangyuan, et al.
Publicado: (2014)

Betacellulin-Induced Beta Cell Proliferation and Regeneration Is Mediated by Activation of ErbB-1 and ErbB-2 Receptors
por: Oh, Yoon Sin, et al.
Publicado: (2011)

Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours
por: Gelardi, T, et al.
Publicado: (2010)

Correlation between HER-2/neu(erbB-2) expression level and therapeutic effect of combination treatment with HERCEPTIN and chemotherapeutic agents in gastric cancer cell lines
por: Cui, Hai, et al.
Publicado: (2014)

cERBB-2/Her-2 Neu Overexpression and Prognostic Significance in Uterine Carcinosarcoma
por: Semiz, Huseyin Salih, et al.
Publicado: (2023)

Homo- and Heteroassociations Drive Activation of ErbB3
por: Váradi, Tímea, et al.
Publicado: (2019)

Expression of Akt kinases related to ErbB2 and results of adjuvant therapy of breast cancer
por: Stal, O, et al.
Publicado: (2000)

Dual targeting of ErbB-2/ErbB-3 results in enhanced antitumor activity in preclinical models of pancreatic cancer
por: Ghasemi, R, et al.
Publicado: (2014)

Targeting of erbB3 receptor to overcome resistance in cancer treatment
por: Ma, Jian, et al.
Publicado: (2014)

HER-3 targeting alters the dimerization pattern of ErbB protein family members in breast carcinomas
por: Karamouzis, Michalis V., et al.
Publicado: (2015)

DMBA promotes ErbB2-mediated carcinogenesis via ErbB2 and estrogen receptor pathway activation and genomic instability
por: Ma, Zhikun, et al.
Publicado: (2018)

Mutational Screening in Tyrosine-Kinase Domain of erbB1 And erbB2 Genes
por: ALONSO, Juan Manuel Fernández
Publicado: (2005)

Clinical relevance of ErbB-2/HER2 nuclear expression in breast cancer
por: Schillaci, Roxana, et al.
Publicado: (2012)

HER/ErbB receptor interactions and signaling patterns in human mammary epithelial cells
por: Zhang, Yi, et al.
Publicado: (2009)

ErbB2/HER2-specific NK cells for adoptive cancer immunotherapy
por: Zhang, Congcong, et al.
Publicado: (2013)

ErbB2/Her2-specific NK cells for adoptive immunotherapy of glioblastoma
por: Zhang, Congcong, et al.
Publicado: (2014)

Progress in the Research and Targeted Therapy of ErbB/HER Receptors in Urothelial Bladder Cancer
por: Chen, Dong, et al.
Publicado: (2021)

Intratumoral delivery of recombinant vaccinia virus encoding for ErbB2/Neu inhibits the growth of salivary gland carcinoma cells
por: Masuelli, Laura, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_nr3b2j0456kjje5o5mo02j5c9e